Back to results
US 5,580,979 AGranted
Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
AssigneeTrustees of Tufts University
InventorWilliam W. Bachovchin
Life of this patent
Estimating the term…
Abstract
The present invention makes available novel compounds represented by the general formula ##STR1## wherein Y represents a phosphate analog. Which compounds are useful for inhibiting an interaction between a protein containing an SH2 domain and a phophotyrosine-containing polypeptide.
Claims8
A compound represented by a general formula:
- ##STR16## wherein R.sub.1 represents hydrogen, a halogen, a lower alkyl, a lower alkenyl, a lower alkynyl, a carboxyl, an azido, --(CH.sub.2).sub.m --R.sub.7, --(CH.sub.2).sub.m --OH, --(CH.sub.2).sub.m --O-lower alkyl, --(CH.sub.2).sub.m --O-lower alkenyl, --(CH.sub.2).sub.n --O--(CH.sub.2).sub.m --R.sub.7, --(CH.sub.2).sub.m --SH, --(CH.sub.2).sub.m --S-lower alkyl, --(CH.sub.2).sub.m --S-lower alkenyl, --(CH.sub.2).sub.n --S--(CH.sub.2).sub.m --R.sub.7, ##STR17## R.sub.4 and R.sub.5 each independently represent hydrogen, lower alkyl, lower alkenyl, --(CH.sub.2).sub.m --R.sub.7, --C(O)-lower alkyl, --C(O)-lower alkenyl, --C(O)--(CH.sub.2).sub.m --R.sub.7,
- or R.sub.4 and R.sub.5 taken together with the N atom to which they are attached complete a heterocyclic ring having from 4 to 8 atoms in the ring structure;
- R.sub.6 represents hydrogen, a lower alkyl, an lower alkenyl, --(CH.sub.2).sub.m --R.sub.7, or a pharmaceutically acceptable salt forming ion;
- R.sub.7 represents an aryl, a cycloalkyl, a cycloakenyl, or a heterocycle;
- R.sub.8 represents hydrogen, a halogen, a lower alkyl, a lower alkenyl, a lower alkynyl, a carboxyl, an azido, --(CH.sub.2).sub.m --R.sub.7, --(CH.sub.2).sub.m --OH, --(CH.sub.2).sub.m --O-lower alkyl, --(CH.sub.2).sub.m --O-lower alkenyl, --(CH.sub.2).sub.n --O--(CH.sub.2).sub.m --R.sub.7, --(CH.sub.2).sub.m --SH, --(CH.sub.2).sub.m --S-lower alkyl, --(CH.sub.2).sub.m --S-lower alkenyl, --(CH.sub.2).sub.n --S--(CH.sub.2).sub.m --R.sub.7, ##STR18## R.sub.10 represents an alpha-carbon sidechain of an amino acid residue;
- R.sub.11 represents COOH or a pharmaceutically acceptable salt thereof or a carboxy-terminal blocking group;
- R.sub.12 represents NH--R.sub.17 or a pharmaceutically acceptable salt thereof, or an amino-terminal blocking group;
- R.sub.14 represents a halogen, a lower alkyl, a lower alkoxy, a lower alkylthio, --NO.sub.2, CF.sub.3, --CN, and --OH;
- R.sub.17 represents hydrogen or a C-terminally linked amino acid residue or peptide;
- Y represents a phosphate or phosphate analog;
- X.sub.1 represents O or S;
- X.sub.2 represents hydrogen, a lower alkyl, --(CH.sub.2).sub.m --OH, --(CH.sub.2).sub.m --O-lower alkyl, a carboxyl, an amine, an amide, a nitrosyl, a sulfhydryl, a sulfonyl, or a sulfonamide;
- n is zero or an integer in the range of 1 to 6;
- m is zero or an integer in the range of 1 to 6;
- and p is an integer in the range of 1 to 6.
12 more elements
A compound represented by a general formula:
- ##STR20## R.sub.8 represents hydrogen or an amino acid sidechain;
- R.sub.10 represents an alpha-carbon sidechain of an amino acid residue;
- R.sub.11 represents COOH or a pharmaceutically acceptable salt thereof, or a carboxy-terminal blocking group;
- R.sub.12 represents NH.sub.2 or a pharmaceutically acceptable salt thereof, or an amino-terminal blocking group;
- and
- Y represents a phosphate or phosphate analog.
3 more elements
Dependencies are inferred from the claim text.